Evidence map›Paper›PMID 32167264›Full record

ArticleTurkish journal of ophthalmology2020

Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma

Hilal Eser Öztürk, Yüksel Süllü

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Turkish journal of ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hilal Eser ÖztürkOndokuz Mayıs University Faculty of Medicine, Department of Ophthalmology, Samsun, TurkeyORCID 0000-0002-0050-7894
Yüksel SüllüOndokuz Mayıs University Faculty of Medicine, Department of Ophthalmology, Samsun, TurkeyORCID 0000-0001-9818-671X
Ondokuz Mayıs University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vemurafenib is a potent inhibitor of genetically activated BRAF, which is responsible for tumoral proliferation in cutaneous melanoma. A 56-year-old man receiving vemurafenib therapy presented with uveitis. Over the course of the disease, he developed bilateral, granulomatous uveitis with multiple peripheral chorioretinal lesions. Serum angiotensin-converting enzyme levels increased. The patient was diagnosed with probable ocular sarcoidosis related to vemurafenib and was treated with an intravitreal dexamethasone implant. This case is the first report that shows the clinical and angiographic features of a patient with vemurafenib-related sarcoid-like granulomatous uveitis.

Indexed as

Antineoplastic AgentsCutaneous Malignant MelanomaFluorescein AngiographyFundus OculiHumansMaleMelanomaMiddle AgedNeoplasm MetastasisSarcoidosisSkin NeoplasmsUveitisVemurafenibAntineoplastic AgentsVemurafenibBRAFMelanomasarcoidosisuveitisvemurafenib

Identifiers

PMID32167264
PMCPMC7086091
OpenAlexW3010570719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.